



High plasma levels of betaine, a trimethylamine N-Oxide-related metabolite, are associated with the severity of cirrhosis

Eline H. van den Berg¹ | Jose L. Flores-Guerrero²  | Erwin Garcia³ |
Margery A. Connelly³ | Vincent E. de Meijer⁴  | TransplantLines Investigators |
Stephan J. L. Bakker² | Hans Blokzijl¹ | Robin P. F. Dullaart⁵

¹Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

²Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

³Laboratory Corporation of America Holdings (Labcorp), Morrisville, North Carolina, USA

⁴Department of Hepatopancreatobiliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands

⁵Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Correspondence

Eline H. van den Berg, Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, The Netherlands, PO Box 30.001, 9700RB Groningen, The Netherlands.
Email: e.h.wouters@umcg.nl

Handling Editor: Alejandro Forner

Abstract

Background and Aims: The gut microbiome-related metabolites betaine and trimethylamine N-oxide (TMAO) affect major health issues. In cirrhosis, betaine metabolism may be diminished because of impaired hepatic betaine homocysteine methyltransferase activity, whereas TMAO generation from trimethylamine may be altered because of impaired hepatic flavin monooxygenase expression. Here, we determined plasma betaine and TMAO levels in patients with end-stage liver disease and assessed their relationships with liver disease severity.

Methods: Plasma betaine and TMAO concentrations were measured by nuclear magnetic resonance spectroscopy in 129 cirrhotic patients (TransplantLines cohort study; NCT03272841) and compared with levels from 4837 participants of the PREVENT cohort study. Disease severity was assessed by Child-Pugh-Turcotte (CPT) classification and Model for End-stage Liver Disease (MELD) score.

Results: Plasma betaine was on average 60% higher ($p < .001$), whereas TMAO was not significantly lower in cirrhotic patients vs. PREVENT population ($p = .44$). After liver transplantation ($n = 13$), betaine decreased ($p = .017$; $p = .36$ vs. PREVENT population), whereas TMAO levels tended to increase ($p = .085$) to higher levels than in the PREVENT population ($p = .003$). Betaine levels were positively associated with the CPT stage and MELD score (both $p < .001$). The association with the MELD score remained in the fully adjusted analysis ($p < .001$). The association of TMAO with the MELD score did not reach significance ($p = .11$). Neither betaine nor TMAO levels were associated with mortality on the waiting list for liver transplantation (adjusted $p = .78$ and $p = .44$, respectively).

Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BHMT, betaine homocysteine methyltransferase; BMI, body mass index; CPT, Child Pugh Turcotte; CPMG, Carr-Purcell-Meiboom-Gill; CV, coefficient of variation; CVD, cardiovascular disease; EDTA, ethylenediaminetetraacetic acid; GGT, gamma-glutamyl transferase; HR, hazard ratio; HDL, high-density lipoproteins; INR, international normalized ratio; IQR, interquartile range; LDL, low-density lipoproteins; MAFLD, metabolic dysfunction-associated fatty liver disease; MELD, Model for End-stage Liver Disease; NMR, nuclear magnetic resonance; OLT, orthotopic liver transplantation; PBC, primary biliary cholangitis; PREVENT, Prevention of Renal and Vascular End-stage Disease; PSC, primary sclerosing cholangitis; SD, standard deviation; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; T2D, type 2 diabetes.

Eline H. van den Berg and Jose L. Flores-Guerrero have contributed equally.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Liver International* published by John Wiley & Sons Ltd.

Conclusion: Plasma betaine levels are elevated in cirrhotic patients in parallel with disease severity and decrease after liver transplantation.

KEYWORDS

betaine, CPT classification, liver cirrhosis, MELD score, NMR spectroscopy, orthotopic liver transplantation, TMAO

1 | INTRODUCTION

Chronic liver diseases represent major health issues and can progress to liver cirrhosis which carries a high mortality risk.^{1,2} Death from chronic liver diseases is globally increasing in the last few decades.³ Recently, evidence is accumulating that the gut microbiome plays a major role in the development of chronic liver diseases and decompensated cirrhosis via translocation of gut microbiota components secondary to increased gut permeability and portal hypertension.^{4,5} Gut microbiota metabolize nutrients including choline to generate betaine (N,N,N-trimethylglycine), and choline and L-carnitine to generate trimethylamine (TMA, N,N-dimethylmethanamine).^{5,6} In the liver, TMA is converted to trimethylamine N-oxide (TMAO, N,N-dimethylmethanamine N-oxide) by flavin monooxygenase3 (FMO3).⁵⁻⁸

Betaine is an osmolyte and serves as a methyl donor in a reaction catalysed by betaine homocysteine methyltransferase (BHMT), which converts homocysteine to methionine.⁹ Plasma betaine was found to be inversely associated with adiposity, blood pressure, and plasma triglycerides and positively with high-density lipoprotein (HDL) cholesterol.¹⁰⁻¹² Low plasma betaine may predict the future development of type 2 diabetes (T2D).¹² Low plasma betaine concentrations were also found in metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH).^{13,14} Betaine may improve oxidative stress, inflammation and apoptosis in an experimental model of MAFLD, probably via its action to decrease homocysteine, and ameliorates hepatic fat accumulation by decreasing homocysteine.^{9,15,16} Betaine may also reduce stellate cell activation in rats with alcoholic liver fibrosis.¹⁷ Consequently, betaine supplementation could ameliorate hepatic steatosis, although the association of betaine with cardiometabolic disorders is not always straightforward and intervention studies so far have not allowed for a definite conclusion.¹⁸ In marked contrast, one study suggested plasma betaine be elevated shortly after liver transplantation.¹⁹ As a contributing mechanism to explain such betaine elevations, BHMT, which converts betaine to dimethylglycine, was found to be impaired in a rat model of liver cirrhosis.²⁰

TMAO has been proposed to be implicated in adverse effects on several health issues.^{6,21} Plasma TMAO has been reported to be associated with all-cause mortality in the general population, particularly in subjects with lower kidney function, and with cardiovascular mortality in T2D patients.^{22,23} Moreover, we found that plasma

Key Points

- In cirrhosis, impaired hepatic betaine homocysteine methyltransferase activity may diminish betaine metabolism; trimethylamine N-oxide generation from trimethylamine may be diminished because of impaired hepatic flavin monooxygenase expression.
- In 129 cirrhotic patients plasma betaine was elevated whereas trimethylamine N-oxide tended to be reduced. In 13 patients who were restudied after orthotopic liver transplantation, these abnormalities were reversed.
- Higher plasma betaine was independently associated with disease severity (MELD score).

TMAO predicts graft failure in kidney transplant recipients.²⁴ On the contrary, circulating TMAO was not found to be associated with (cardiovascular) mortality in haemodialysis patients²⁵ and was not associated with an adverse cardiometabolic risk profile in children.²⁶ Remarkably little is known about the role of TMAO in chronic liver disease. Plasma TMAO independently predicted all-cause mortality in subjects with MAFLD,²⁷ but to our knowledge, there are no studies on circulating TMAO in patients with cirrhotic liver disease. FMO3 protein expression in microsomes from human cirrhotic livers is reduced in relation to increasing disease severity as judged by Child Pugh Turcotte (CPT) classification.²⁸ It is, therefore, plausible to postulate that generation of TMAO from TMA is impaired in end-stage cirrhotic liver disease.

Nuclear magnetic resonance (NMR) spectroscopy-based assays for betaine and TMAO have been recently developed which allow for their large-scale measurement in human plasma.^{12,29} So far, effects of end-stage liver disease on circulating levels of betaine and TMAO have been scarcely reported. We, therefore, initiated the present study on plasma concentrations of betaine and TMAO in patients with end-stage liver disease on the waiting list for orthotopic liver transplantation (OLT). Our aims were to determine: (1) to which extent plasma betaine and TMAO, assayed by NMR spectroscopy, are altered in end-stage liver disease and to document the effect of OLT, (2) associations of plasma betaine and TMAO with disease severity, and (3) associations of betaine and TMAO with mortality whilst on the waiting list for OLT.

2 | MATERIALS AND METHODS

2.1 | Study populations

This report follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. Participants of the TransplantLines cohort study were used as a group of patients with end-stage liver disease. TransplantLines is a transplant biobank and cohort study carried out in the University Medical Center Groningen, The Netherlands (NCT03272841).³⁰ The study was approved by the Medical Ethics Committee of the University Medical Center Groningen (METc 2014/077) and is performed in accordance with the Declaration of Helsinki guidelines. All participants provided written informed consent. Exclusion criteria were no mastery of the Dutch language and inability to intellectually understand questionnaires or physical tests.³⁰ There were 129 patients with cirrhotic end-stage liver disease who were screened for OLT and in whom NMR-determined betaine and TMAO measurements were available. Thirteen of these patients were restudied 3–6 months after OLT.

As a control group, the study population of the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort study was used.^{31,32} The PREVEND study was approved by the Medical Ethics Committee of the University Medical Centre Groningen (MEC96/01/022) and is performed in accordance with the Declaration of Helsinki guidelines. Written informed consent was obtained from all participants. PREVEND is a large prospective general population-based study, which was initiated to investigate cardiovascular and renal disease. All inhabitants (28 to 75 years old) of Groningen, the Netherlands were sent a questionnaire on demographics and cardiovascular morbidity. Pregnant women, type 1 diabetic subjects and T2D subjects using insulin were excluded from participation.^{31,32} We used data of participants who completed the second screening round (2001–2003) and who were free from liver disease assessed by questionnaire ($n = 6894$). Participants with missing measurements for plasma betaine and TMAO were excluded, leaving 4837 PREVEND participants.

2.2 | Data collection and measurements

TransplantLines has a continuous data collection which started on June 2015. For the present study data were collected up to December 2020. During visits to the outpatient clinic, questionnaires and blood samples were collected from all participants according to the TransplantLines protocol. At the time of blood collection patients continued their regular medication. A standardized protocol was used to obtain anthropometric measurements. Patient information, including weight, height, body mass index (BMI), smoking status, medication use (glucose and lipid-lowering drugs) and medical histories such as cardiovascular disease (CVD) and diabetes, was extracted from the TransplantLines Biobank. Additional review of all electronic patient records of study participants was performed to obtain additional data concerning the aetiology of liver disease

and cirrhotic state (based on imaging, histology or transient elastography), and biochemical and clinical variables to calculate the Model for End-stage Liver Disease (MELD) and CPT scores as scores to assess the severity of the end-stage liver disease. The MELD score was calculated by serum bilirubin, creatinine and international normalized ratio (INR).^{33,34} The CPT score was calculated by total bilirubin, serum albumin, INR, ascites and hepatic encephalopathy.³⁵ In the PREVEND cohort data were collected on demographics, lifestyle factors, anthropometric measurements, medical history and medication use, which was combined with information from a pharmacy-dispensing registry as previously described.^{22,32} In both TransplantLines and PREVEND venous blood samples were drawn after an overnight fast.

2.3 | Laboratory analysis

Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine, high sensitivity C-reactive protein (hsCRP) and plasma glucose were analysed with standardized laboratory measurements and quality assessment control at the department of Laboratory Medicine of the University Medical Centre Groningen. Laboratory methods for PREVEND are reported as described in detail previously.^{31,32,36}

Ethylenediaminetetraacetic acid (EDTA)-anticoagulated plasma samples were obtained by centrifugation at 1400 g for 15 min at 4°C and then stored at -80°C until analysis. EDTA-anticoagulated plasma samples for betaine, TMAO and lipoprotein profiles were measured using a Vantera Clinical Analyser (Labcorp), a fully automated, high-throughput, 400 MHz proton (¹H) NMR spectroscopy platform.³⁷ For lipoprotein profiles, plasma samples were prepared on board the instrument, and automatically delivered to the flow probe in the NMR spectrometer's magnetic field.³⁷ Data acquisition on the Vantera and the spectra data processing have been reported in greater detail elsewhere.^{37–39} Total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were measured employing the LP4 algorithm.^{40,41} Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation. Non-HDL cholesterol was calculated as total cholesterol minus HDL cholesterol.

Plasma betaine and TMAO were quantified from one-dimensional proton Carr-Purcell-Meiboom-Gill (CPMG) spectra using a deconvolution assay as previously described.^{12,29} In brief, plasma specimens were mixed with citrate/phosphate buffer (3:1 v/v) to lower the pH to 5.3, which was necessary to separate the betaine and TMAO signals that otherwise overlap at physiological pH. Betaine assay results are linear over a wide range of concentrations (26.0–1135 $\mu\text{mol/L}$). Coefficients of variation for intra- and inter-assay precision are up to 4.3% and 5.5%, respectively. Betaine as measured by the NMR assay give comparable results with mass spectrometry (MS) ($R^2 = 0.94$). For TMAO, linearity was demonstrated up to 3000 $\mu\text{mol/L}$. Coefficients of variation are up to 4.3% and 9.8% for intra- and interassay precision, respectively. TMAO measurements by NMR compare well with

values obtained by a MS-based assay ($R^2 = 0.98$). Plasma choline in cirrhotic patients was measured by NMR from the same CPMG spectra used to generate the betaine and TMAO results. The newly developed NMR assay quantifies choline using a non-negative deconvolution algorithm.⁴² Linearity was demonstrated up to 239.3 μM in plasma. Coefficients of variation are approximately 11% for intra- and interassay precision. Choline measured by the NMR assay is comparable to that of mass spectrometry ($R = 0.998$).

2.4 | Statistical analysis

Statistical analyses were performed with IBM SPSS software (version 23.0 Armonk, NY: IBM Corp) and R language for statistical computing software (version 4.0.3 [2020], Vienna, Austria). Continuous variables are expressed as median with interquartile range (IQR) or as numbers with percentages. Normality of distribution was assessed and checked for skewness. Differences in variables between the cirrhotic patients and PREVEND participants were determined by Mann-Whitney U tests or by Chi-square tests where appropriate. Differences in betaine and TMAO according to cause of death were evaluated by Mann-Whitney U tests. Kruskal Wallis analysis of variance (ANOVA) was used to assess the relation of betaine and TMAO with the CPT category. Univariate correlations were analysed by Spearman rank correlation coefficients. Multivariable logistic regression analyses were carried out to disclose the independent contribution of variables to plasma betaine and TMAO. To this end, betaine and TMAO were Ln-transformed to achieve an approximately normal distribution. Betaine and TMAO levels before and after OLT were compared by the Wilcoxon test. Kaplan-Meier curves with the log-rank test were performed to determine the effect of betaine and TMAO below and above their median values of the whole group of cirrhotic patients on mortality on the waiting list with the date of OLT as the census date. Cox proportional hazards models were used to compute hazard ratios (HRs) and 95%CI of betaine and TMAO expressed per 1 Ln SD increment on mortality risk on the waiting list. HRs were calculated in models adjusted for age, sex and MELD score. Two-sided p -values of $<.05$ were considered statistically significant.

3 | RESULTS

There were 129 patients with cirrhosis who participated in the study. Their clinical and laboratory characteristics were compared with 4837 healthy controls of the PREVEND study (Table 1). Mean age, as well as a history of cardiovascular disease and T2D, were not different between the groups. Amongst cirrhotic patients relatively more men were included and more participants had a history of diabetes. BMI was higher and blood pressure was lower in cirrhotic patients. Bilirubin, liver enzymes and hsCRP levels were all higher in cirrhotic patients. Plasma total cholesterol, non-HDL cholesterol, LDL cholesterol and triglycerides were all lower in cirrhotic patients.

Plasma betaine was on average 60% higher ($p <.001$), whereas TMAO was not significantly lower in cirrhotic patients ($p = .44$) compared to the values in the PREVEND cohort. Consequently, the betaine/TMAO ratio was on average 80% higher in cirrhotic patients ($p <.001$) (Table 1). Plasma betaine ($p <.001$) and the betaine/TMAO ratio ($p = .050$) remained higher in cirrhotic patients after adjustment for age, sex, CVD, diabetes history and medication use. Also, the difference in plasma TMAO did not reach significance after these adjustments ($p = .22$). There was no significant correlation between plasma betaine and TMAO in cirrhotic patients ($r = -.042$, $p = .64$). In the PREVEND group, this correlation was of similar magnitude but reached significance ($r = -.038$; $p = .007$) (data not shown). As provided in Table 2, plasma betaine and TMAO concentrations did not significantly vary according to liver disease aetiology, except for plasma TMAO which tended to be lower in cirrhosis because of MAFLD and cholestatic liver disease.

Of the end-stage cirrhotic patients, 13 were again studied 3–6 months after OLT. In these patients, plasma betaine decreased from 59.7 (39.8–116.0) to 38.1 (31.1–50.4) $\mu\text{mol/L}$ ($p = .017$). In turn, plasma TMAO changed from 3.0 (1.25–8.1) to 7.4 (1.6–14.4) $\mu\text{mol/L}$ ($p = .085$). The betaine levels attained after follow-up were not different from those in the PREVEND population (Table 1) ($p = .36$), whereas TMAO was higher in the OLT recipients than the values in the PREVEND population (Table 1) ($p = .003$). In this subset, plasma choline measurements were available and increased from 5.80 (3.75–7.65) to 9.50 (7.05–12.15) $\mu\text{mol/L}$ after OLT ($p = .002$). Furthermore, plasma betaine was not correlated with choline in these 13 cirrhotic patients before OLT ($r = .066$, $p = .83$) but did correlate with choline after transplantation ($r = .615$, $p = .025$). Plasma TMAO was unrelated to choline before ($r = .014$, $p = .96$) and after OLT ($r = -.022$, $p = .94$).

In univariable analysis, plasma betaine was associated with the CPT stage as well as with the MELD score (Figure 1A,B), but TMAO was not significantly associated with the CPT stage and only modestly with the MELD score (Figure 2A,B). Multivariable logistic regression analysis demonstrated that the association of betaine with the MELD score was stronger than that with the CPT classification. This association remained significant after adjustment for underlying liver disease aetiology, plasma lipids, hsCRP and the use of lipid-lowering and glucose-lowering drugs (Table 3). There was a modest association of TMAO with the MELD score which lost formal significance after full adjustment ($p = .11$, Table 4).

The median follow-up on the waiting list was 140 (IQR 52–381) days. Twenty-nine (22.5%) patients died whilst on the waiting list for liver transplantation (Table 1), of whom 12 died from multi-organ failure, 5 patients from end-stage liver disease-related complications, 4 from malignancy, 3 from cardiovascular disease and the rest from other causes. Kaplan Meier curves showed that mortality on the waiting list was not significantly different between patients with plasma betaine or TMAO above and below the median value of the whole cirrhotic group (Figure 3). As shown in Table 5 Cox regression analysis demonstrated that the association of plasma betaine (expressed per 1 SD increase)

TABLE 1 Clinical and laboratory characteristics including betaine and TMAO in 129 patients with end-stage cirrhotic liver disease and 4837 PREVEND participants

	Cirrhotic patients N = 129	PREVEND participants N = 4837	p-value
Baseline characteristics			
Sex: men/women, n (%)	84 (65.1)/45 (34.9)	2388 (49.4)/2449 (50.6)	<.001
Age (years), median (IQR)	60 (52–65)	53 (44–63)	.650
BMI (kg/m ²), median (IQR)	28.0 (24.2–30.9)	26.1 (23.7–28.9)	.006
BMI			
Normal; ≤25 kg/m ² , n (%)	28 (31.1)	1882 (38.9)	.132
Overweight; 25–30 kg/m ² , n (%)	32 (35.6)	2043 (42.2)	.203
Obese; ≥30 kg/m ² , n (%)	30 (33.3)	912 (18.9)	.001
Systolic blood pressure (mmHg), median (IQR)	115 (107–130)	123 (112–137)	.001
Diastolic blood pressure (mmHg), median (IQR)	65 (59–75)	72 (67–79)	<.001
Smoking, n (%)	16 (18.8)	1321 (27.3)	.081
Child Pugh Turcotte classification			
Child Pugh Turcotte A, n (%)	28 (21.7)	n.a.	n.a.
Child Pugh Turcotte B, n (%)	63 (48.8)		
Child Pugh Turcotte C, n (%)	38 (29.5)		
MELD score, median (IQR)	15 (10–19)	n.a.	n.a.
Mortality on waiting list, n (%)	29 (22.5)	n.a.	n.a.
History of cardiovascular disease, n (%)	6 (4.8)	301 (6.2)	.514
History of diabetes, n (%)	36 (28.8)	294 (6.1)	<.001
Glucose lowering drugs, n (%)	35 (32.1)	178 (3.7)	<.001
Lipid-lowering drugs, n (%)	19 (17.4)	458 (9.5)	.005
Blood tests			
Creatinine (μmol/L), median (IQR)	79.0 (62.5–102.0)	83.2 (73.9–92.4)	.163
Fasting glucose (mmol/L), median (IQR)	6.4 (5.0–8.5)	4.8 (4.4–5.3)	<.001
Total cholesterol (mmol/L), median (IQR)	3.2 (2.5–4.2)	5.3 (4.7–6.1)	<.001
Non-HDL cholesterol (mmol/L), median (IQR)	2.2 (1.7–3.0)	4.1 (3.4–4.8)	<.001
HDL cholesterol (mmol/L), median (IQR)	0.9 (0.4–1.2)	1.2 (1.0–1.4)	<.001
LDL cholesterol (mmol/L), median (IQR)	1.8 (1.3–2.3)	3.5 (2.9–4.1)	<.001
Triglycerides (mmol/L), median (IQR)	0.7 (0.5–1.1)	1.1 (0.8–1.6)	<.001
ALT (U/L), median (IQR)	40.0 (28.0–60.0)	17.0 (13.0–24.0)	<.001
AST (U/L), median (IQR)	54.0 (44.0–84.0)	22.0 (19.0–26.0)	<.001
GGT (U/L), median (IQR)	95.0 (48.0–151.0)	24.0 (16.0–38.0)	<.001
ALP (U/L), median (IQR)	141.0 (98.0–217.0)	66.0 (55.0–79.0)	<.001
Bilirubin total (μmol/L), median (IQR)	42.0 (23.0–99.3)	7.0 (5.0–9.0)	<.001
CRP(mg/L), median (IQR)	10.0 (4.3–25.5)	1.3 (0.6–3.0)	<.001
Betaine (μmol/L), median (IQR)	59.7 (46.9–75.6)	36.7 (30.7–43.6)	<.001
TMAO (μmol/L), median (IQR)	3.0 (1.4–6.1)	3.2 (1.7–5.6)	.44
Betaine/TMAO ratio, median (IQR)	21.2 (9.3–54.3)	11.6 (6.3–21.5)	<.001

Note: Data are given in numbers with percentages (%) or median with interquartile ranges (IQR).

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; HDL, high-density lipoproteins; LDL, low-density lipoproteins; MELD score, the model for end-stage liver disease.

with mortality on the waiting list was not significant. There was a trend towards a positive association of plasma TMAO with mortality on the waiting list in crude and age- and sex-adjusted analysis, which was lost after additional adjustment for MELD score. There

were no differences in plasma betaine and TMAO concentrations according to cause of death except for lower plasma betaine levels amongst those who died from multi-organ failure compared to other causes ($p = .024$, data not shown).

TABLE 2 Plasma betaine and TMAO levels and betaine/TMAO ratio according to aetiology of primary liver diseases in 129 patients with end-stage cirrhotic liver disease

	N	Betaine ($\mu\text{mol/L}$)	p-value	TMAO ($\mu\text{mol/L}$)	p-value	Betaine/TMAO ratio	p-value ^a
Aetiology of primary liver disease							
Cholestatic liver disease (PSC/PBC)	34	53.2 (45.6–79.8)	.38	2.9 (1.5–12.1)	.086	21.6 (4.6–51.7)	.98
Storage disease	4	67.4 (61.8–93.7)	.94	2.4 (0.6–28.9)	.26	48.7 (5.9–148.3)	.87
MAFLD	33	57.2 (44.9–76.6)	.25	2.7 (1.2–4.4)	.053	30.1 (13.8–51.9)	.74
Alcohol	28	67.8 (45.0–87.8)	.19	3.2 (1.1–6.2)	.39	21.7 (9.1–61.2)	.28
Viral	12	53.9 (38.6–62.1)	.34	3.4 (2.1–15.9)	.32	13.4 (7.3–29.5)	.24
Autoimmune hepatitis	11	71.4 (43.2–100.7)	.61	5.3 (1.4–10.8)	.14	12.7 (4.6–61.0)	.71
Storage disease	4	67.4 (61.8–93.7)	.94	2.4 (0.6–28.9)	.26	48.7 (5.9–148.3)	.87
Vascular	2	66.8	.90	3.6	.56	36.5	.72
Other	5	47.8 (36.2–57.7)	.20	2.1 (0.8–5.9)	.56	31.6 (8.6–100.8)	.72

Note: Data are given in medians with interquartile ranges (IQR). As $N = 2$, no IQR can be presented for vascular liver disease.

Abbreviations: MAFLD, metabolic associated fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

^aAdjusted for age and sex and compared to other aetiologies of primary liver diseases.




FIGURE 1 Plasma concentrations of betaine according to Child-Pugh Turcotte stage and MELD scores in 129 cirrhotic patients. Left panel: Boxplots of plasma betaine concentrations according to Child-Pugh Turcotte stage (bars represent median betaine values) ($p < .001$ by ANOVA). Right panel: Relationship of plasma betaine concentrations with MELD score (Spearman rank correlation coefficient: .46, $p < .001$).

4 | DISCUSSION

The present study demonstrates that plasma betaine concentrations are considerably increased whereas TMAO concentrations tend to be decreased in patients with cirrhosis compared to the levels found in the general population. In a small subset of patients who were followed after OLT, plasma betaine returned to levels that were not different from those in the general population. TMAO levels after liver transplantation appeared to be higher than those in the general population. Plasma betaine elevations were found across all the various aetiologies underlying end-stage liver disease. Higher plasma betaine concentrations were associated with the higher

CPT category and were strongly associated with the MELD score. The positive association with the MELD score remained in the fully adjusted analysis. In contrast, plasma TMAO levels were not independently associated with disease severity. Combined, these results suggest that end-stage liver cirrhotic liver disease may be implicated in plasma betaine elevations.

Plasma betaine was on average 60% higher in end-stage liver cirrhosis. Plasma betaine elevations as documented here appear to be in line with recent findings suggesting high plasma betaine levels amongst 74 Chinese patients measured one day after a living donor liver transplantation procedure, although the precise concentrations were not reported in that study.¹⁹ Choline is an important precursor




FIGURE 2 Plasma concentrations of TMAO according to Child-Pugh Turcotte stage and MELD scores in 129 cirrhotic patients. Left panel: Boxplots of plasma TMAO concentrations according to Child-Pugh Turcotte stage (bars represent median TMAO values) ($p = .14$ by ANOVA). Right panel: Relationship of plasma TMAO concentrations with MELD score (Spearman rank correlation coefficient: $.22$, $p = .01$)

TABLE 3 Multivariable linear regression analyses demonstrating independent associations of plasma betaine in 129 end-stage cirrhotic patients

	Model 1		Model 2		Model 3		Model 4	
	β	p -value	β	p -value	β	p -value	β	p -value
Age (years)	-0.035	.695	0.025	.760	0.001	.988	0.030	.758
Sex (women vs. men)	-0.025	.778	-0.005	.953	-0.078	.346	-0.077	.378
Child Pugh classification (A/B/C)	0.265	.003			-0.014	.895	0.021	.849
MELD score			0.472	<.001	0.748	<.001	0.782	<.001
Total cholesterol					-0.363	.008	-0.361	.012
Triglycerides					0.234	.085	0.238	.091
HDL cholesterol					0.206	.075	0.239	.054
HsCRP					-0.139	.165	-0.137	.184
Lipid-lowering drugs (yes/no)							-0.122	.188
Glucose lowering drugs (yes/no)							0.077	.411

Note: All models are mutually adjusted for the variables included in the analyses.

Abbreviations: HDL, high-density lipoprotein, MELD score, the model for end-stage liver disease score.

of betaine. Indeed, plasma betaine was positively correlated with choline in the small subset of patients who were restudied after liver transplantation, whilst no such relationship was observed before transplantation. Enhanced choline availability is an unlikely mechanism responsible for high plasma betaine in cirrhosis since choline deficiency is common in cirrhotic patients who are often malnourished,⁴³ and choline supplementation seems justified in this patient category.⁴⁴ Instead, it is plausible that cirrhosis-induced BHMT deficiency, as shown both at the mRNA level and expressed as protein activity in a rat model of bile duct ligation-induced liver cirrhosis,²⁰ is at least in part responsible for plasma betaine elevations in cirrhosis. In line with this possibility, plasma betaine was strongly and positively related to disease severity as demonstrated by its association

with the CPT category and the MELD score, the latter association being independent of relevant clinical and laboratory characteristics including lipids and lipoproteins (deemed necessary to adjust for given their relationships with betaine¹⁰⁻¹²). In addition, plasma betaine decreased to levels as found in the general population in those patients who could be followed after liver transplantation, further corroborating the impact of cirrhosis on betaine metabolism.

In contrast to high plasma betaine, TMAO tended to be lower in cirrhotic patients. As a result, the betaine/TMAO ratio was on average 80% higher in cirrhotic patients. Plasma TMAO tended to increase after liver transplantation to levels that were higher than those in the general population. We found only very modest relationships between TMAO and betaine in the cirrhotic group as well

TABLE 4 Multivariable linear regression analyses demonstrating independent associations of plasma TMAO in 129 end-stage cirrhotic patients

	Model 1		Model 2		Model 3		Model 4	
	β	p-value	β	p-value	β	p-value	β	p-value
Age (years)	0.201	.027	0.221	.015	0.246	.037	0.322	.012
Sex (women vs. men)	-0.039	.655	-0.031	.724	-0.020	.851	-0.035	.762
Child Pugh classification (A/B/C)	0.119	.186			-0.081	.562	-0.090	.536
MELD score			0.182	.043	0.195	.199	0.256	.108
Total cholesterol					0.256	.143	0.237	.199
Triglycerides					-0.194	.263	-0.195	.286
HDL cholesterol					-0.190	.199	-0.145	.364
CRP					0.141	.275	0.139	.300
Lipid-lowering drugs (yes/no)							-0.112	.353
Glucose lowering drugs (yes/no)							-0.033	.789

Note: OR: odds ratio. CI 95%: 95% confidence interval. All models are mutually adjusted for the variables included in the analyses.

Abbreviations: MELD score, the model for end-stage liver disease score, TMAO, Trimethylamine N-oxide.




FIGURE 3 Kaplan-Meier plots for all-cause mortality on the waiting list for liver transplantation. Left panel: comparison of participants subjects above and below the median plasma betaine concentration ($p = .28$ for the log-rank test). Right panel: comparison of participants subjects above and below the median plasma TMAO ($p = .089$ for the log-rank test).

TABLE 5 Association of plasma Betaine (A) and plasma TMAO (B) with mortality on the waiting list

	HR per 1 SD increase	p-value
A. Betaine		
Model 1	1.08 [0.75;1.54]	.69
Model 2	1.11 [0.76;1.61]	.58
Model 3	0.94 [0.60;1.47]	.78
B. TMAO		
Model 1	1.53 [0.97;2.41]	.06
Model 2	1.48 [0.95;2.31]	.08
Model 3	1.18 [0.77;1.81]	.45

Note: Plasma betaine and TMAO are Ln transformed. Models 1: crude. Models 2: adjusted for age and sex. Models 3: adjusted for age, sex and MELD score.

Abbreviations: MELD score, the model for end-stage liver disease score, TMAO, Trimethylamine N-oxide.

as in the PREVENDE population in accordance with the previous findings.¹² A diet intervention study in rats has suggested that betaine provides only a minor source of TMAO.⁴⁵ Choline deficiency could contribute to low plasma TMAO in liver cirrhosis, although

in our study TMAO was unrelated to choline before and after OLT. Impaired conversion of TMA to TMAO in the liver consequent to hepatic FMO3 deficiency could also play a role.²⁸

Using mortality on the waiting list for OLT as a clinical end-point we did not find a significant association with plasma betaine in crude nor adjusted analysis. The reason for the lack of effect of plasma betaine on waiting list mortality is not known. Betaine may have beneficial effects on oxidative and inflammatory processes involved in liver injury but this effect of betaine is most likely attributable to its action to lower homocysteine via the BHMT activity pathway,^{9,15,16} the pathway which we specifically propose to be disturbed in cirrhosis. In comparison, in the post-liver transplantation study from China, early graft dysfunction was to a minor extent predicted by higher plasma betaine levels alone, but its predictive ability was improved when combined with other phospholipid and fatty acid biomarkers.¹⁹ On the contrary, higher plasma TMAO tended to be positively associated with waiting-list mortality in crude Cox regression analysis which was downsized after adjustment for the MELD score. This would raise the possibility of a dual effect of TMAO. A putative detrimental effect of circulating TMAO per se, in keeping with the notion that TMAO could adversely affect health,^{6,21} combined with lower TMAO generation, consequent to cirrhosis

severity. Additionally, betaine appeared to be lower in subjects who died from multi-organ failure, conceivably as a consequence of more advanced disease severity. Our findings should be regarded as preliminary. Besides the absence of formal statistical significance of the associations of betaine and TMAO with mortality on the waiting list, it is not clear whether betaine and TMAO could be regarded as mere markers of liver disease severity rather than as causative factors implicated in prognosis.

Strengths of this study include combined betaine and TMAO measurements in a considerable group of cirrhotic patients with a detailed and standardized assessment of clinical and laboratory characteristics consequent to the TransplantLines Biobank and Cohort study set-up³⁰ in comparison with data from the PREVEND study,^{12,27} which served as a large community-dwelling control cohort. Limitations of our study include the absence of detailed information regarding dietary intake and composition, gut microbiome data, as well as the absence of plasma choline measurements in the whole cirrhotic group and the PREVEND population. Plasma TMA measurements were not available because their concentration is too low to allow for its accurate assay using NMR spectroscopy. Furthermore, we carried out a single-centre study which can limit its external validity. Also, only a limited number of participants could be studied after liver transplantation. In fact, if such plasma TMAO elevations are confirmed in a larger liver transplantation cohort, this would warrant diet intervention in this patient category.

In conclusion, plasma betaine is elevated in cirrhotic patients, likely returns to levels found in the general population after OLT and are positively associated with disease severity. In contrast, plasma TMAO tends to be lower in cirrhosis and could be elevated after OLT. A possible association of betaine and TMAO with cirrhosis-related mortality deserves further study.

AUTHOR CONTRIBUTIONS

Conception and design of study: EB, JLFG, and RD. Data collection: EB, JLFG, EG, MAC, and RD. Data analysis: EB, JLFG, and RD. Interpretation of data: EB, JLFG, EG, MAC, VM, SB, HB, and RD. Drafting the manuscript: EB, JLFG, and RD. All authors have revised and approved the submitted manuscript.

FUNDING INFORMATION

The TransplantLines Biobank was supported by a grant from Astellas BV. The Dutch Kidney Foundation supported the infrastructure of the PREVEND program from 1997 to 2003 (Grant E.033). The University Medical Center Groningen supported the infrastructure from 2003 to 2006. The Dutch Heart Foundation supported studies on lipid metabolism (Grant 2001-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr Flores-Guerrero is supported by a grant from the National Council of Science and Technology.

CONFLICT OF INTEREST

EG and MAC are employees of Labcorp, carried out the NMR measurements, and assisted with the interpretation of the data. Labcorp

was not involved in the study design, data analysis, nor the decision to publish the results. VM reports a VENI research grant by the Netherlands Organization for Scientific Research (NWO; grant #09150161810030), a Research grant from the Dutch Ministry of Economic Affairs (Health-Holland Public Private Partnership grant #PPP-2019-024), and a Research grant from the Dutch Society for Gastroenterology (NVGE; #01-2021), all outside the submitted work. All other authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

Data are available upon reasonable request.

ORCID

Jose L. Flores-Guerrero  <https://orcid.org/0000-0002-6094-2206>

Vincent E. de Meijer  <https://orcid.org/0000-0002-7900-5917>

REFERENCES

1. Byass P. The global burden of liver disease: a challenge for methods and for public health. *BMC Med.* 2014;12:159.
2. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol.* 2019;70(1):151-171.
3. Collaborators GBDC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. *Lancet Gastroenterol Hepatol.* 2020;5(3):245-266.
4. Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. *Nat Rev Gastroenterol Hepatol.* 2021;18(3):167-180.
5. Schoeler MC R. Dietary lipids, gut microbiota and lipid metabolism. *Rev Endocr Metab Disord.* 2019;20(4):461-472.
6. Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic Axis implicated in health and disease. *Drug Metab Dispos.* 2016;44(11):1839-1850.
7. Dolphin CT, Cullingford TE, Shephard EA, Smith RL, Phillips IR. Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FMO4. *Eur J Biochem.* 1996;235(3):683-689.
8. Lang DH, Yeung CK, Peter RM, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. *Biochem Pharmacol.* 1998;56(8):1005-1012.
9. Day CR, Kempson SA. Betaine chemistry, roles, and potential use in liver disease. *Biochim Biophys Acta.* 2016;1860(6):1098-1106.
10. Konstantinova SV, Tell GS, Vollset SE, Nygard O, Bleie O, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. *J Nutr.* 2008;138(5):914-920.
11. Dullaart RP, Garcia E, Jeyarajah E, Gruppen EG, Connelly MA. Plasma phospholipid transfer protein activity is inversely associated with betaine in diabetic and non-diabetic subjects. *Lipids Health Dis.* 2016;15(1):143.
12. Garcia E, Oste MCJ, Bennett DW, et al. High betaine, a trimethylamine N-oxide related metabolite, is prospectively associated with low future risk of type 2 diabetes mellitus in the PREVEND study. *J Clin Med.* 2019;8(11):1813.
13. Chen YM, Liu Y, Zhou RF, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. *Sci Rep.* 2016;6:19076.

14. Sookoian S, Puri P, Castano GO, et al. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. *Liver Int.* 2017;37(4):611-619.
15. Veskovik M, Mladenovic D, Milenkovic M, et al. Betaine modulates oxidative stress, inflammation, apoptosis, autophagy, and Akt/mTOR signaling in methionine-choline deficiency-induced fatty liver disease. *Eur J Pharmacol.* 2019;848:39-48.
16. Ahn CW, Jun DS, Na JD, Choi YJ, Kim YC. Alleviation of hepatic fat accumulation by betaine involves reduction of homocysteine via up-regulation of betaine-homocysteine methyltransferase (BHMT). *Biochem Biophys Res Commun.* 2016;477(3):440-447.
17. Bingul I, Basaran-Kucukgergin C, Aydin AF, et al. Betaine treatment decreased oxidative stress, inflammation, and stellate cell activation in rats with alcoholic liver fibrosis. *Environ Toxicol Pharmacol.* 2016;45:170-178.
18. Mukherjee S. Role of betaine in liver disease-worth revisiting or has the die been cast? *World J Gastroenterol.* 2020;26(38):5745-5748.
19. Tsai HI, Lo CJ, Lee CW, et al. A panel of biomarkers in the prediction for early allograft dysfunction and mortality after living donor liver transplantation. *Am J Transl Res.* 2021;13(1):372-382.
20. Forestier M, Banninger R, Reichen J, Solioz M. Betaine homocysteine methyltransferase: gene cloning and expression analysis in rat liver cirrhosis. *Biochim Biophys Acta.* 2003;1638(1):29-34.
21. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature.* 2011;472(7341):57-63.
22. Gruppen EG, Garcia E, Connelly MA, et al. TMAO is associated with mortality: impact of modestly impaired renal function. *Sci Rep.* 2017;7(1):13781.
23. Flores-Guerrero JL, van Dijk PR, Connelly MA, et al. Circulating trimethylamine N-oxide is associated with increased risk of cardiovascular mortality in Type-2 diabetes: results from a Dutch diabetes cohort (ZODIAC-59). *J Clin Med.* 2021;10(11):2269.
24. Flores-Guerrero JL, Oste MCJ, Baraldi PB, et al. Association of Circulating Trimethylamine N-oxide and its dietary determinants with the risk of kidney graft failure: results of the TransplantLines cohort study. *Nutrients.* 2021;13(1):262.
25. Kaysen GA, Johansen KL, Chertow GM, et al. Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis. *J Ren Nutr.* 2015;25(4):351-356.
26. Andraos S, Jones B, Lange K, et al. Trimethylamine N-oxide (TMAO) is not associated with cardiometabolic phenotypes and inflammatory markers in children and adults. *Curr Dev Nutr.* 2021;5(1):nzaa179.
27. Flores-Guerrero JL, Post A, van Dijk PR, et al. Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease. *Liver Int.* 2021;41(10):2371-2382.
28. El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. *Mol Pharm.* 2021;18(9):3563-3577.
29. Garcia E, Wolak-Dinsmore J, Wang Z, et al. NMR quantification of trimethylamine-N-oxide in human serum and plasma in the clinical laboratory setting. *Clin Biochem.* 2017;50(16-17):947-955.
30. Eisenga MF, Gomes-Neto AW, van Londen M, et al. Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients. *BMJ Open.* 2018;8(12):e024502.
31. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. The effect of cholesteryl ester transfer protein -629C->a promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. *J Clin Endocrinol Metab.* 2005;90(7):4198-4204.
32. Kappelle PJ, Gansevoort RT, Hillege JL, Wolffenbuttel BH, Dullaart RP, PREVEND Study Group. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. *J Intern Med.* 2011;269(2):232-242.
33. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology.* 2001;33(2):464-470.
34. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology.* 2003;124(1):91-96.
35. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg.* 1973;60(8):646-649.
36. van den Berg EH, Flores-Guerrero JL, Gruppen EG, et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids. *Nutrients.* 2019;11(3):705.
37. Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. NMR measurement of LDL particle number using the Vantera clinical analyzer. *Clin Biochem.* 2014;47(16-17):203-210.
38. Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. HDL particle number measured on the Vantera(R), the first clinical NMR analyzer. *Clin Biochem.* 2015;48(3):148-155.
39. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. *Clin Lab Med.* 2006;26(4):847-870.
40. Bedi S, Garcia E, Jeyarajah EJ, et al. Characterization of LP-Z lipoprotein particles and quantification in subjects with liver disease using a newly developed NMR-based assay. *J Clin Med.* 2020;9(9):2915.
41. Garcia E, Bennett DW, Connelly MA, et al. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and apolipoprotein B. *Lipids Health Dis.* 2020;19(1):247.
42. Garcia E, Shalurova I, Matyus SP, Wolak-Dinsmore J, Oskardmay DN, Connelly MA. Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. *Clin Chim Acta.* 2022;524:106-112.
43. Chawla RK, Wolf DC, Kutner MH, Bonkovsky HL. Choline may be an essential nutrient in malnourished patients with cirrhosis. *Gastroenterology.* 1989;97(6):1514-1520.
44. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. *Curr Opin Gastroenterol.* 2012;28(2):159-165.
45. Yu ZL, Zhang LY, Jiang XM, et al. Effects of dietary choline, betaine, and L-carnitine on the generation of trimethylamine-N-oxide in healthy mice. *J Food Sci.* 2020;85(7):2207-2215.

How to cite this article: van den Berg EH, Flores-Guerrero JL, Garcia E, et al.. High plasma levels of betaine, a trimethylamine N-Oxide-related metabolite, are associated with the severity of cirrhosis. *Liver Int.* 2022;00:1-10. doi: [10.1111/liv.15310](https://doi.org/10.1111/liv.15310)